Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

NCT01495572 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

NIH

Sponsor class

Stopped Due to slow accrual, the investigator decided to close the study.

Conditions

Metastatic Melanoma
Skin Cancer

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Aldesleukin
DRUG: MART-1 Reactive CD8+ PBL

Sponsor

National Cancer Institute (NCI)